Whether or not the $74 billion acquisition succeeds for Bristol-Myers, its impact on biotech will be wide-reaching by erasing Celgene, one of the industry's most active dealmakers.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,